Thousands of ME/CFS patients are facing an uncertain wait after health officials delayed crucial new treatment guidelines amid fierce controversy over therapies that some say cause more harm than good. The National Institute for Health and Care Excellence (NICE) has postponed publication of its updated recommendations following significant pushback from patient groups over the inclusion of graded exercise therapy and certain psychological treatments.
The updated guidelines were set to replace NICE's 2007 recommendations for Myalgic Encephalomyelitis (ME), also known as Chronic Fatigue Syndrome (CFS). However, the process has hit major obstacles due to strong objections from patient advocacy groups and individuals living with the condition. These groups argue that graded exercise therapy (GET) – which involves gradually increasing physical activity – can be actively harmful to patients, potentially worsening their symptoms and quality of life.
Patient organisations also contend that whilst cognitive behavioural therapy (CBT) may help with coping strategies, it should not be presented as a treatment or cure for what they emphasise are genuine physical symptoms. The delay highlights the sensitive nature of ME/CFS care, where past approaches focusing on behavioural interventions have left many patients feeling dismissed or inadequately treated.
ME/CFS is a long-term neurological condition characterised by debilitating fatigue, pain, and other symptoms that can severely impact daily functioning. According to NHS estimates, the condition affects around 250,000 people in the UK, though many cases remain undiagnosed. NICE has indicated that further consideration is required to address stakeholder concerns and ensure the guidance is both robust and evidence-based.
The controversy reflects a long-standing divide within the medical community regarding ME/CFS understanding and treatment. For decades, the condition was sometimes dismissed or attributed solely to psychological factors, leading to inadequate medical care and limited research funding. However, advances in understanding have gradually shifted perspectives, emphasising the condition's biological basis and the need for treatments that address complex physiological symptoms.
The Department of Health and Social Care has previously acknowledged the urgent need for updated ME/CFS guidance, recognising the challenges faced by patients and the importance of evidence-based care. NICE's decision to delay publication reflects the delicate balance required to develop guidelines that are scientifically sound, ethically responsible, and responsive to patients' lived experiences.
Patient organisations, including the ME Association and Action for ME, have been vocal throughout the guideline development process, advocating for recommendations that prioritise patient safety and effective symptom management. Their persistent feedback has proved crucial in highlighting these concerns, prompting NICE to re-evaluate key aspects of the draft guidance before final publication. The outcome of this review will have significant implications for how ME/CFS is diagnosed and managed across the NHS.